Evidence map›Paper›PMID 18350160›Full record

ArticlePloS one2008

Application of in vivo induced antigen technology (IVIAT) to Bacillus anthracis.

Sean M Rollins, Amanda Peppercorn, John S Young, Melissa Drysdale, Andrea Baresch, Margaret V Bikowski, David A Ashford, Conrad P Quinn, Martin Handfield, Jeffrey D Hillman and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Sean M RollinsMassachusetts General Hospital, Boston, Massachusetts, United States of America. srollins1@partners.org
Amanda Peppercorn
John S Young
Melissa Drysdale
Andrea Baresch
Margaret V Bikowski
David A Ashford
Conrad P Quinn
Martin Handfield
Jeffrey D Hillman
C Rick Lyons
Theresa M Koehler
Stephen B Calderwood
Edward T Ryan
Massachusetts General Hospital · USUniversity of New Mexico · USCenters for Disease Control and Prevention · USHarvard University · USMass General Brigham · USOragenics (United States) · USUnited States Department of Agriculture · USUniversity of Florida · US

Funding

Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI FINBERG, ROBERT WILLIAM · 2003 to 2013
$113.7M
WRCE Nonhuman Primate CoreU54AI057156 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 2003 to 2013
$102.6M
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
VIRULENCE GENE EXPRESSION BY BACILLUS ANTHRACISR01AI033537 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KOEHLER, THERESA M. · 1998 to 2020
$5.4M
IN VIVO INDUCED ANTIGEN TECHNOLOGY OF AA IN LJPR01DE013523 · NIDCR · UNIVERSITY OF FLORIDA · PI HANDFIELD, MARTIN · 2000 to 2003
$990k
Application of IVIAT to Bacillus anthracisR21AI053442 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 2003 to 2004
$617k
CONTROL OF PROTECTIVE ANTIGEN SYNTHESIS BY B ANTHRACISR29AI033537 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KOEHLER, THERESA M. · 1993 to 1997
–
NIAID NIH HHS AI053442NIAID NIH HHS AI33537NIAID NIH HHS R01 AI033537NIAID NIH HHS R21 AI053442NIAID NIH HHS T32 AI007061NIAID NIH HHS T32 AI07061NIAID NIH HHS U54 AI057156NIAID NIH HHS U54 AI057159NIDCR NIH HHS DE13523NIDCR NIH HHS R01 DE013523PHS HHS N01-A1-40053
6 · The paper itself

Abstract

In vivo induced antigen technology (IVIAT) is an immuno-screening technique that identifies bacterial antigens expressed during infection and not during standard in vitro culturing conditions. We applied IVIAT to Bacillus anthracis and identified PagA, seven members of a N-acetylmuramoyl-L-alanine amidase autolysin family, three P60 family lipoproteins, two transporters, spore cortex lytic protein SleB, a penicillin binding protein, a putative prophage holin, respiratory nitrate reductase NarG, and three proteins of unknown function. Using quantitative real-time PCR comparing RNA isolated from in vitro cultured B. anthracis to RNA isolated from BALB/c mice infected with virulent Ames strain B. anthracis, we confirmed induced expression in vivo for a subset of B. anthracis genes identified by IVIAT, including L-alanine amidases BA3767, BA4073, and amiA (pXO2-42); the bacteriophage holin gene BA4074; and pagA (pXO1-110). The exogenous addition of two purified putative autolysins identified by IVIAT, N-acetylmuramoyl-L-alanine amidases BA0485 and BA2446, to vegetative B. anthracis cell suspensions induced a species-specific change in bacterial morphology and reduction in viable bacterial cells. Many of the proteins identified in our screen are predicted to affect peptidoglycan re-modeling, and our results support significant cell wall structural remodeling activity during B. anthracis infection. Identification of L-alanine amidases with B. anthracis specificity may suggest new potential therapeutic targets.

Indexed as

AnimalsAntigens, BacterialBacillus anthracisGene Expression ProfilingMacaca mulattaMiceMice, Inbred BALB CReverse Transcriptase Polymerase Chain ReactionRNA, MessengerAntigens, BacterialRNA, Messenger

Identifiers

PMID18350160
PMCPMC2265799
OpenAlexW2077282651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.